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Abstract
To examine the relation between measures of adiposity and depressive symptoms in a large well
characterized community-based sample, we examined the relations of visceral adipose tissue
(VAT) and subcutaneous adipose tissue (SAT) to depressive symptoms in 1581 women (mean age
52.2 years) and 1718 men (mean age 49.8 years) in the Framingham Heart Study. Depressive
symptoms were measured using the Center for Epidemiologic Studies Depression (CES-D) scale.
Regression models were created to examine the association between each fat depot (exposure) and
depressive symptoms (outcome). Sex specific models were adjusted for age, body mass index,
smoking, alcohol consumption, diabetes, hypertension, total and HDL cholesterol, lipid lowering
treatment, CVD, menopause, C-reactive protein, and physical activity. Mean CES-D scores were
6.8 and 5.6 in women and men. High levels of depressive symptoms were present in 22.5% of
women and 12.3% of men. In women, one standard deviation increase in VAT was associated
with a 1.3 point higher CES-D score after adjusting for age and BMI (p<0.01) and remained
significant in the fully adjusted model (p=0.03). The odds ratio of depressive symptoms per 1
standard deviation increase in VAT in women was 1.33 (p=0.015); results were attenuated in fully
adjusted models (OR 1.29, p=0.055). In men, the association between VAT and CES-D score and
depressive symptoms was not significant. SAT was not associated with CES-D score or depressive
symptoms. This study supports an association between VAT and depressive symptoms in women.
Further work is needed to uncover the complex biologic mechanisms mediating the association.
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Introduction
Depressive symptoms are common, often occur in adolescence or early adulthood, and are
associated with an increased risk for type 2 diabetes, cardiovascular disease (CVD) events
and all-cause mortality.(1-3) However, the underlying biologic mechanisms mediating these
associations remain under investigation. Adiposity may be one potential pathway through
which depressive symptoms contribute to diabetes and CVD risk. The relation between
depression and adiposity appears to be bidirectional (4) and may be modified by gender and
fat distribution. Depression is associated with greater adiposity in women (5) and depressive
symptoms increase risk for abdominal obesity in community-dwelling elders.(6) Conversely,
obesity, particularly visceral adiposity, is associated with increased risk of new depressive
symptoms in older men but not older women.(7) Small studies, mostly in women,
demonstrate that depressed patients have higher amounts of visceral adipose tissue (VAT)
compared with non-depressed individuals.(8) In a study of middle-aged women (mean age
50 years, over 70% overweight or obese), VAT, but not subcutaneous adipose tissue (SAT)
or waist circumference, was related to depressive symptoms.(9) These data suggest a
complex relationship between adiposity and depressive symptoms with additional research
needed in large community-based samples that include younger and middle-aged men and
women with assessment of overall obesity as well as measurement of specific fat depots.
We sought to examine the relation between measures of adiposity and depressive symptoms
in a large well characterized community-based sample of both men and women. Our sample
included men and women across adulthood (age 31 to 83 years) and across a wide range of
body mass index levels (15.8 to 55.9 kg/m2). We hypothesized that individuals with greater
amounts of VAT and SAT would be at increased risk for the presence of high levels of
depressive symptoms even after adjustment for overall obesity and other important potential
confounding factors. Further, we hypothesized that relationships would be stronger for
VAT, a fat depot strongly associated with adverse metabolic risk(10) and increased
inflammation and oxidative stress(11), pathways that may provide an important link
between adiposity and depressive symptoms.
Methods and Procedures
Study Sample
Participants for this study were drawn from the Framingham Heart Study (FHS) Multi-
detector Computed Tomography (MDCT) Study, a substudy of the community-based
Framingham Offspring and Third Generation (Gen 3) cohorts.(10) The FHS was initiated in
1948 to study determinants of cardiovascular disease and other health conditions. Beginning
in 1971 the Offspring of the Original Cohort members and Offspring spouses were enrolled
(n=5124) and from 2002 to 2005 Gen 3 participants with at least one parent in the Offspring
cohort were enrolled (n=4095). Details of study design of Offspring and Gen 3 cohorts have
been previously reported.(12;13)
From 2002 to 2005, 3529 participants (2111 Gen 3 and 1418 Offspring participants)
underwent MDCT assessment for coronary and aortic calcification and 3370 had measures
of both SAT and VAT.(10) Among this group, 23 did not undergo assessment of depressive
symptoms, 30 had incomplete depression information (missing CES-D survey score or
information on antidepressant medication use) and 18 did not have complete risk factor
information, leaving 3299 for this study. The Institutional Review Board at Boston
University Medical Center approved this study and all participants provided written
informed consent.
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Measures of VAT and SAT
Eight-slice multi-detector computed tomography scanning of the abdomen was obtained as
previously described (LightSpeed Ultra, General Electric, Milwaukee, WI).(14) We
measured SAT and VAT volumes (Aquarius 3D Workstation, TeraRecon Inc., San Mateo,
CA), which required the reader to manually trace the abdominal muscular wall, which
separates the subcutaneous and visceral fat compartments. Applying an image display
window of -195 to -45 Hounsfield Units (HU) results in semi-automatic quantification of
SAT and VAT volumes. Inter-class correlations for inter-reader comparisons were 0.997 for
SAT and 0.992 for VAT; correlations for intra-reader comparisons were similarly high.(14)
Measure of Depressive Symptoms
Depressive symptoms were assessed with the 20-item Center for Epidemiologic Studies
Depression (CES-D) Scale developed and validated by the Center for Epidemiologic
Studies, National Institute of Mental Health. Trained technicians administered the CES-D to
Gen 3 participants attending Gen 3 examination 1 (2002-2005) and to Offspring participants
attending Offspring examination 7 (1998-2001). The mean time between CES-D assessment
and MDCT assessment of SAT and VAT was 0.2 years (0.38 SD) in Gen 3 participants and
4.2 years (0.95 SD) in Offspring participants. Participants were asked to provide responses
to the 20 items that corresponded to how they were feeling during the past week with
response choice options of: 0=rarely or none of the time (< 1day), 1=some or a little of the
time (1-2 days), 2=occasionally or a moderate amount of time (3-4 days), and 3=most or all
of the time (5 to 7 days). The CES-D was then scored by summing the coded response
values for all 20 items with the total scale score range of 0 to 60. A score of 16 or higher
was designated as consistent with the presence of depressive symptoms in accordance with
previous recommendations.(15) If a participant had missing responses for more than 5 items,
then the CES-D score was set to missing (n=29) and the participant was excluded from this
study whereas if one to five items was missing (n=211) then the non-missing scale items
were totaled and the total score divided by the number of non-missing items and this value
was then multipled by 20. In addition, participants were queried by trained physicians
regarding use of anti-depressant medications. At Gen 3 exam 1, participants were asked to
bring all medication bottles to the research examination to further verify self-reported
medication use. If a participant was missing antidepressant use status (n=1), the participant
was excluded.
Covariates and potential confounders
Covariates were measured at the closest examination (Gen 3 exam 1 and Offspring exam 7
respectively). Height, weight, and waist circumference were directly measured by trained
technicians and body mass index (BMI) was calculated as the weight in kilograms divided
by the height in meters squared. A technician-administered physical activity questionnaire
was used to calculate a physical activity index score based on the average number of hours
daily of sleep and sedentary, slight, moderate and high activity the participant reported.
Medication use, smoking status and alcohol consumption were recorded as part of the
standard physician-administered medical history interview. Current smoking was defined as
smoking at least one cigarette per day over the year preceding the exam. Moderate alcohol
intake was defined as greater than 14 drinks per week in men and greater than 7 drinks per
week in women. Women were additionally queried about menopausal status and
postmenopausal hormone use with a standard series of questions. Hypertension was defined
using physician obtained blood pressure readings as ≥140/90 mm Hg or use of anti-
hypertensive medications. Fasting morning blood samples were used to measure fasting
plasma glucose, total and high density lipoprotein (HDL) cholesterol, and C-reactive
protein. Diabetes was defined as a fasting glucose ≥126 mg/dL or use of insulin or oral
hypoglycemic agents. Prevalent CVD was defined using previously published criteria and
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included coronary heart disease, congestive heart failure, stroke or transient ischemic attack
and intermittent claudication.(16)
Statistical methods
The relationship between adiposity and each of the following two depressive symptoms
outcomes was examined: a continuous total CES-D score and high levels of depressive
symptoms (a dichotomous CES-D score ≥16 and/or use of anti-depressant medications).
Specifically, the cross-sectional relation between SAT and VAT (modeled as the exposure)
and depressive symptoms (modeled as the outcomes) was assessed using multivariable
linear (for CES-D score) and logistic regression (for presence of high levels of depressive
symptoms) with separate models for SAT and VAT. All models were sex specific due to the
presence of a significant VAT x sex interaction (p=0.001) in the initial model adjusted for
age, sex, and BMI with CES-D score as the dependent variable. We did not find any
significant VAT x cohort interaction (Offspring vs Gen 3) or SAT x cohort interaction with
CES-D score or high levels of depressive symptoms (all p values > 0.10) therefore we did
not run separate models by cohort. The effects of adiposity on depressive symptoms are
presented as the mean change in CES-D score and change in odds of high levels of
depressive symptoms per 1 standard deviation increment increase in SAT or VAT. Because
anti-depressant medication use may affect the CES-D score, in the linear regression we first
imputed the CES-D score for participants on antidepressant medications following a similar
algorithm previously used by Framingham investigators to impute blood pressure readings
for individuals on anti-hypertensive agents.(17) Specifically, we imputed CES-D scores for
each participant with self-reported anti-depressant use by replacing the participant’s
observed CES-D score with the mean CES-D score of all participants reporting anti-
depressant medication use having the same or higher score. Thus, with the imputation
procedure it was assumed that individuals on anti-depressants with the lowest CES-D scores
had a larger antidepressant effect than individuals with higher CES-D scores. Initial linear
and logistic models were adjusted for age and BMI and then full multivariable models were
further adjusted for smoking status, alcohol consumption, diabetes, prevalent CVD,
hypertension, total cholesterol, HDL cholesterol, lipid lowering treatment, and menopausal
status. In secondary analyses we further adjusted for C-reactive protein and physical
activity. All statistical analyses were performed using SAS version 9.1.
Results
The study sample comprised 1581 women (mean age 52.2 years) and 1718 men (mean age
49.8 years) with mean BMI in the overweight category and characteristics typical of a
community-based sample (Table 1). As expected, the mean CES-D score was higher in
women than men (imputed score 6.8 vs. 5.6; raw score 3.5 vs 2.6) as was the prevalence of
CES-D score ≥ 16 (11.8% vs. 7.3%) and use of anti-depressant medications (15.0% vs.
6.9%). Thus, the presence of high levels of depressive symptoms (CES-D ≥16 and/or
antidepressant medication use) was higher in women than men (22.5% vs. 12.3%).
Estimates of the increment in mean CES-D score per 1 standard deviation increase in VAT
or SAT for each linear regression model are presented in Table 2. In women, one standard
deviation increase in VAT was associated with an average increase in CES-D of 1.3 after
adjusting for age and BMI (p<0.01). The estimate remained significant and only slightly
attenuated in the fully adjusted model (1.1 point mean higher CES-D score per standard
deviation of VAT) and was not further attenuated after adjustment for C-reactive protein or
the physical activity index. No association between VAT and CES-D score was seen in men.
There was no association between SAT and CES-D score in women or men. We repeated
the analysis using raw CES-D scores without imputation. The relation between VAT and
depressive symptoms in women persisted but with an attenuation in the effect. In women,
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one standard deviation increase in VAT was associated with an average increase in CES-D
score of 1.1 after adjusting for age, BMI and antidepressant medication use (p=0.005) and an
average increase in CES-D score of 0.8 in fully adjusted models (p=0.05).
Women had 1.33 times the odds of high levels of depressive symptoms per one standard
deviation increase in VAT after adjusting for age and BMI (p<0.015) (Table 3). The
increased odds of high levels of depressive symptoms associated with VAT were attenuated
in the covariate adjusted model (OR 1.27, p=0.055) and in the model adjusted for C-reactive
protein and physical activity (OR 1.29, p=0.055). In men, in the age and BMI adjusted
model, the odds of high levels of depressive symptoms per standard deviation increase in
VAT was 1.24 (p=0.052) but the association was no longer significant in the fully adjusted
model (odds 1.14, p=0.27). SAT was not associated with increased odds of high levels of
depressive symptoms in women or men (Table 3).
Discussion
Principal findings
Our large community-based study of middle-aged individuals demonstrates a cross-sectional
relation between VAT and depressive symptoms in women but in our sample there was not
an association in men. The relation persisted after adjustment for overall obesity (body mass
index) and important confounders such as menopausal status and markers of inflammation
(C-reactive protein) which may represent potential pathways linking adiposity and
depression. Adiposity, particularly VAT, and depressive symptoms are both associated with
increased inflammation. (18) No relation between SAT and depressive symptoms was
observed in women or men. The heterogeneity of the associations in the two fat depots may
highlight the differences in metabolic activity within each fat depot. Specifically, VAT is a
unique pathogenic fat depot that consists of metabolically active adipose tissue.(19) In
contrast, SAT may serve as an ectopic fat reservoir and as such has been considered to be a
potential protective fat depot in animal studies (20;21) although the literature in humans is
less convincing.(21) Our study makes an important contribution to the literature by
investigating a large community-based sample of both men and women across adulthood
including both pre- and postmenopausal women and across a wide range of BMI levels
using volumetric measures of VAT and objective measures of overall obesity and potential
confounders.
In the context of the current literature
Much of the existing literature has focused on anthropometric measurements and
correlations with depressive indices. A recent meta-analysis demonstrated a bidirectional
relation between obesity and depression such that obese persons (BMI ≥30 kg/m2) were at
increased risk of developing depression over time and depressed individuals were at
increased risk of becoming obese.(4) Further, there appeared to be a dose-response relation
as associations were stronger in obese compared to overweight individuals. In a large
population-based sample of US women, BMI was associated with moderate-to-severe
depressive symptoms and major depression.(22) In that report abdominal obesity, measured
by waist circumference, was also positively associated with depressive symptoms
independent of BMI. A second large community-based study (the second Health Survey of
North-Trondelag County Norway, the HUNT-2 Study) also reported an association between
abdominal obesity, defined with waist-hip ratio, and depression in both women and men.
(23) While additional studies have also found a relation between depressive symptoms and
waist circumference or waist-hip ratio in women (24), other studies have not found an
association between abdominal obesity and depression.(25)
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Few studies have examined the association between VAT and depressive symptoms.
Consistent with findings from our study, depressive symptoms were strongly associated with
VAT in a study of mostly overweight and obese peri- and postmenopausal women (9) and in
a small study of overweight premenopausal women.(26) Interestingly, in a study of older
high functioning adults aged 70 to 79 at baseline, VAT was predictive of the onset of
depressive symptoms in men but not in women in contrast to our findings (7) whereas the
presence of depressive symptoms were associated with an increase in VAT over 5 years
independent of BMI.(6) Our study extends the previous reports in several important ways.
First, we included a large community-based sample of both men and women with ages
spanning early and mid-adulthood. Our sample was well characterized with respect to both
directly measured anthropometry assessment as well as important potential confounding
factors. Finally, we obtained volumetric measures of VAT. The association of VAT and
depressive symptoms in women in our sample was present even after adjustment for BMI,
covariates, measures of inflammation and physical activity.
Potential Mechanisms
The biologic mechanisms mediating the obesity-depressive symptoms relation remain
poorly understood, however several potential mechanisms have been proposed including
inflammation, hypothalamic-pituitary-adrenal axis (HPA) dysregulation and
hypercortisolemia, and hormonal milieu. In addition, physical activity is an important causal
factor for obesity (27) and is known to improve depressive symptoms.(28) While it is well
known that excess adiposity is associated with increased inflammation, VAT is associated
with increased inflammation even after accounting for BMI and waist circumference (16)
suggesting a unique and important contribution of VAT to the inflammatory state.
Inflammation in turn has been associated with depression and depressive symptoms in both
healthy adults(29) and individuals with coronary syndromes(30). In the Study of Women’s
Health Across the Nation, higher C-reactive protein levels were associated with increased
depressive symptoms and the association appeared to be bidirectional.(18) Similar findings
were noted in a study of older adults, such that depressed mood was causing and/or caused
by increased inflammation. (31) Thus, inflammation appears to play an important role in
both adiposity and depressive symptoms and may be one mediator of the association
between the two conditions. Similarly the transition to menopause and changes in the
hormonal milieu in postmenopausal women have been associated with both changes in fat
distribution(32) and increased depressive symptoms. (33) Menopause is significantly
associated with VAT independent of aging and the effect appears to be mediated through
sex hormone levels (higher bioavailable testosterone or lower sex hormone binding
globulin) independent of total body adiposity.(32) Women with abdominal obesity have
both central and peripheral alterations in the HPA axis(34) and HPA dysregulation has been
linked to depression. Hence, there are likely to be multiple biologic mechanisms linking
adiposity and depressive symptoms some of which may play a more important role in
women than men. Our future work will focus on repeat assessment of measures of
depressive symptoms and SAT and VAT which will allow us to examine the bi-
directionality of the relation as well to examine whether inflammation and reproductive
status are related to changes in fat distribution and depressive symptoms.
Limitations
Our study has some limitations that merit comment. First, our sample was white of
European ancestry and thus findings cannot be generalized to other race/ethnicities. In at
least one study, no relation was identified between depressive symptoms and visceral fat
accumulation in older black women.(6) Second, the CES-D was used to detect depressive
symptoms rather than clinical diagnostic criteria. Although the CES-D has been validated in
psychiatric and community-based samples and is predictive of mortality and CVD events in
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national surveys and longitudinal cohort studies(1), it is possible that relations with visceral
fat would differ if a clinically diagnosed ascertainment was evaluated. In a meta-analysis of
obesity defined by BMI category the association was stronger in individuals with a clinical
diagnosis of depressive disorder than in those with depressive symptoms.(4) While we
included antidepressant medication usage in our definitions of depressive symptoms, we
cannot assess the impact of specific classes of anti-depressant medications on weight gain
and adiposity. We did not assess diet which may be an important confounder in the
adiposity-depressive symptoms relation. A recent report demonstrated elevated CES-D
scores were associated with poorer-quality diet.(24) Physical activity improves both mood
and adiposity and may provide an important link between the two conditions. Finally our
study is cross-sectional and cannot infer causality. Further, the time between the CES-D
measurement and MDCT assessment for SAT and VAT was 4.2 years in the Offspring
cohort. However, the relationships between depressive symptoms and fat are similar to the
findings we present in the manuscript when CES-D is modeled as the exposure variable with
SAT and VAT modeled as the outcome variable. No relation between depressive symptoms
(defined as a continuous score or the presence of high levels of depressive symptoms) and
SAT was observed in women or men. In our sample, there was no association between
depressive symptoms and VAT in men. However, in women one standard deviation increase
in total CES-D score was associated with 28 cm3 higher VAT (p=0.01 in the fully adjusted
model) and the presence of high depressive symptoms was associated with 55 cm3 higher
VAT (p=0.07 in the fully adjusted model); results not previously presented.
Conclusions
Our community-based study results suggest a significant relation between VAT and
depressive symptoms in middle-aged women that is independent of overall obesity and
important confounders. Depressive symptoms and obesity are both common conditions with
significant adverse effects on health that may be greater when the two conditions occur
together. Further work is warranted to determine if VAT, a metabolically active adipose
tissue depot, mediates the association between depressive symptoms and risk for CVD and
type 2 diabetes and to develop effective prevention and intervention strategies to ameliorate
these two common debilitating conditions.
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Table 1
Characteristics of the Study Sample at Assessment of Depressive Symptoms
Mean (SD) or % (N) Women
N=1581
Men
N=1718
Characteristics Mean or % SD or N Mean or % SD or N
Age, years 52.2 9.9 49.8 10.7
Education, < high school, % 1.0 15 1.9 30
Education, high school graduate, % 56.3 815 46.3 735
Education, > high school, % 42.6 616 51.9 824
Body mass index, kg/m2 27.0 5.8 28.4 4.5
Waist circumference, cm 93 16 101 12
Current smoking, % 12.4 196 13.4 230
Moderate alcohol intake, % 14.8 234 16.2 279
Menopausal status, % 50.5 798 NA NA
Diabetes, % 5.4 86 7.4 127
Hypertension, % 26.7 422 32.0 549
Total/HDL cholesterol ratio 3.5 1.1 4.5 1.4
Lipid lowering treatment, % 10.6 167 17.8 305
Prevalent CVD, % 4.2 67 7.9 135
C-reactive proteina, mg/L 1.69 0.65, 4.27 1.21 0.57, 2.70
Physical activity index 36.7 5.7 38.3 8.9
Exposures
SAT, cm3 3135 1510 2633 1201
VAT, cm3 1359 834 2241 1022
Outcomes
Raw CES-D score 3.5 5.2 2.6 5.1
Imputed CES-D score 6.8 7.6 5.6 6.2
Raw CES-D ≥16 and/or antidepressant medication use, % 22.5 356 12.3 211
Components of outcomes
Raw CES-D ≥16, % 11.8 187 7.3 125
Antidepressant medication use, % 15.0 237 6.9 119
Moderate alcohol intake defined as > 14 drinks/week in men and > 7 drinks/week in women
CES-D= Center for Epidemiologic Studies Depression
CVD=cardiovascular disease
HDL= high density lipoprotein
SD=standard deviation
SAT= subcutaneous adipose tissue
VAT= visceral adipose tissue
a
Median, 25th, 75th percentile provided
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